Ketamine therapy — what the research actually says

Ketamine has been used as an anesthetic since the 1960s. Its emergence as a mental health treatment is more recent — and more significant than most people realize. For people with treatment-resistant depression, ketamine represents something genuinely new: a fast-acting intervention that works through a completely different mechanism than traditional antidepressants, often producing results within hours rather than weeks. That’s not hype. That’s what the data shows.

What ketamine is

Ketamine is a dissociative anesthetic — meaning it produces a sense of detachment from one’s surroundings and self at higher doses. At the sub-anesthetic doses used in mental health treatment, it produces a range of effects including mild dissociation, altered sensory perception, and often a profound shift in emotional state and perspective.

Unlike classical psychedelics like psilocybin or LSD, which primarily act on serotonin receptors, ketamine works primarily as an NMDA receptor antagonist — it blocks a type of glutamate receptor in the brain. Glutamate is the brain’s primary excitatory neurotransmitter, and the NMDA receptor plays a central role in synaptic plasticity — the brain’s ability to form and reorganize connections. This mechanism is thought to be key to ketamine’s antidepressant effects.

How it works as an antidepressant

Traditional antidepressants — SSRIs, SNRIs, and others — work primarily by modulating serotonin, norepinephrine, or dopamine systems. They typically take four to six weeks to produce meaningful effects, and a significant proportion of people don’t respond adequately to them.

Ketamine works differently. By blocking NMDA receptors, it triggers a cascade of neurobiological changes including a rapid increase in glutamate activity and the release of BDNF (brain-derived neurotrophic factor), a protein involved in the growth and maintenance of neurons. This appears to rapidly restore synaptic connections in prefrontal cortex circuits that become degraded in depression — essentially promoting neuroplasticity in areas of the brain most affected by depressive illness.

The result is antidepressant effects that can emerge within hours of a single infusion — something no previous antidepressant has been able to achieve. For people in acute crisis, or those who have failed multiple antidepressant trials, this speed is clinically significant.

The two main forms of ketamine treatment

What the evidence shows

The evidence base for ketamine in treatment-resistant depression is genuinely strong — particularly for rapid reduction of depressive symptoms and suicidal ideation. Multiple randomized controlled trials and meta-analyses have found significant antidepressant effects compared to placebo, with response rates in the range of 50-70% for treatment-resistant populations who have failed two or more antidepressant trials.

The evidence for anti-suicidal effects is particularly notable. Studies have found that ketamine can reduce suicidal ideation within hours — a clinically critical window where no other pharmacological intervention works this quickly. This has led to its use in acute crisis settings.

The main limitation of ketamine treatment is durability. Antidepressant effects from a single infusion typically last one to two weeks. Repeated infusion series and maintenance infusions are often needed to sustain benefits. Long-term data is still accumulating, and questions about optimal maintenance protocols and long-term safety remain active areas of research.

Ketamine-assisted psychotherapy

A growing number of clinicians integrate psychotherapy with ketamine treatment — using the neuroplastic window opened by ketamine to do deeper therapeutic work. The dissociative and perspective-shifting properties of the ketamine experience can facilitate insights and emotional processing that are harder to access in ordinary states of consciousness.

Ketamine-assisted psychotherapy (KAP) typically involves preparation sessions before the medicine session, the infusion itself with a therapist present, and integration sessions afterward to process the experience and consolidate insights. Research on KAP specifically — as opposed to ketamine infusions alone — is still developing, but preliminary findings and clinical reports are promising.

Who ketamine treatment is appropriate for

Ketamine treatment is primarily indicated for:

• Treatment-resistant depression — typically defined as failing to respond adequately to two or more antidepressant trials
• Major depressive disorder with acute suicidal ideation
• Bipolar depression (with careful monitoring and usually alongside a mood stabilizer)
• Some anxiety disorders and OCD — evidence is emerging but less robust than for depression
• PTSD — some evidence, particularly for KAP protocols

Ketamine is not appropriate for everyone. Contraindications include a personal or family history of psychosis or schizophrenia, active substance use disorder (particularly stimulants or dissociatives), uncontrolled hypertension, and certain other medical conditions. A thorough medical and psychiatric evaluation is required before beginning treatment.

Important considerations and risks

Ketamine has abuse potential — it’s a Schedule III controlled substance in the US, and problematic use patterns exist, particularly with intranasal or oral forms obtained outside clinical settings. Clinical ketamine treatment involves careful dosing, supervised administration, and monitoring specifically to mitigate these risks.

The proliferation of ketamine clinics — particularly telehealth-based at-home ketamine programs — has raised legitimate questions about screening practices, safety monitoring, and appropriate patient selection. If you’re considering ketamine treatment, working with a reputable clinic that conducts thorough medical and psychiatric evaluation, provides proper monitoring during sessions, and offers integration support is important.

Ketamine treatment is a significant medical intervention. It should be pursued in consultation with qualified psychiatric and medical providers — not as a first-line treatment, but as a carefully considered option when other approaches haven’t worked or when speed of response is clinically critical.